Abstract
Background
Hypospadias is one of the most common forms of congenital malformation of the male external genitalia worldwide. The ratio in the Iranian population is one in 250 live male births. The conversion of testosterone to dihydrotestosterone (DHT) in the presence of steroid 5α-reductase 2, which is encoded by SRD5A2 gene, plays an important role in the normal development of the male reproductive system.
Methods
We examined whether SRD5A2 gene mutations (V89L and A49T polymorphisms) are associated with the risk of hypospadias in the Iranian population. We performed exons sequencing for SRD5A2 gene in 109 hypospadias patients.
Results
We identified two new mutations in the subgroups of affected cases: including a substitution of the nucleotide T > A in the codon 73 [c.219T > A (p.Leu73_Ser74insHisPro)] and an insertion of an extra A nucleotide in the codon 77 [c.229insA* (p.Gly77*)]. Additionally, we performed PCR–RFLP for the two identified polymorphisms and revealed that V89L [OR = 5.8, 95% CI (3.8–8.8), p value < 0.001] and A49T [OR = 10.16, 95% CI (3.94–26.25), p value < 0.001] are significantly associated with hypospadias occurrence in patients. Our haplotype analysis further indicated that the Leu–Ala haplotype increases risk of hypospadias; conversely, the Val–Ala haplotype decreases the risk of hypospadias in the studied patients.
Conclusions
This study demonstrates that polymorphisms in the SRD5A2 gene could be considered as a risk factor for hypospadias disease emergence.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Hypospadias is the second most common congenital malformation of the male external genitalia after cryptorchidism [1], affecting one in 200–300 live male births [2]. Hypospadias disease is often associated with a penile curvature (Chordee) [3]. Classification of hypospadias phenotypes depends on the severity of the anatomical displacement of the urethral meatus [4, 5]. This disease is classified into three groups including mild, moderate and severe. The mild phenotype is the distal form in which the urethra opens on the anterior body of the penis (glandular, subcoronal). The moderate phenotype refers to defects in the middle portion of the penis (distal penile, mid shaft, proximal penile). The severe phenotype is the proximal type which involves posterior penile (penoscrotal, scrotal, perineal) [5].
Normal development of male reproductive tissue, including the urethra, requires testosterone and dihydrotestosterone (DHT) [6]. Testosterone is converted to the more potent androgen, DHT, by an enzyme known as asteroid 5α-reductase 2. This enzyme is encoded by the SRD5A2 gene (OMIM: 607306) that is located on chromosome 2p23 [7, 8]. DHT deficiency affects the normal differentiation of male external genitalia, as well as the maturity of male secondary sexual traits during puberty [9]; and the DHT synthesis is variably impaired, depending on the residual activity of the mutated protein [10]. Previous studies have shown that mutations in SRD5A2 may lead to a reduction of its enzyme activity and result in various degrees of masculinization defects, including hypospadias [11–15].
Recently, Dung and colleagues have reported the novel missense mutation (c.659 C > T; pS220L) in the patients with 46,XY disorder of sex development (DSD) [16]. Moreover, the IVS1-2A > G splice mutation has been reported in the Cypriot patients to cause 5α-reductase deficiency [17]. Furthermore, two polymorphisms in SRD5A2, including V89L (a substitution of valine by leucine at codon 89 due to a G > C transversion, rs523349) [18] and A49T (substitution of alanine by threonine at codon 49 due to a G to A transition, rs9282858), have been shown to be associated with hypospadias in different populations [19–21]. In the present study, we sought to identify whether the specific genotypes of SRD5A2 are related with the risk of hypospadias in the Iranian population.
Materials and methods
Experimental subjects
Hundred and nine blood samples were collected from patients with hypospadias at Mofid Children’s Hospital. The criteria for selecting participants in the study included diagnosis by urologist, and having no sign of other genetic or congenital disease or genital malformations, the characteristic of patients in our study are depicted in Table S1. These patients were categorized according to the phenotypes of hypospadias and the presence of Chordee. A total of 109 matched controls from the Shahid Beheshti School of Medicine hospital without hypospadias or any history of genital abnormalities who visited the urologist for some other reasons were collected via person to person surveys and were confirmed by a urologist. Demographic and clinical data pertaining to the reproductive profile of each participant and their and family, as well as genital abnormalities, were recorded for cases and controls. Peripheral blood samples of hypospadic patient and control groups were taken using Venoject tubes containing EDTA (0.5 M). DNA samples were extracted using DNA extraction kits according to the manufacturer’s protocol (Qiagen,Valencia, California).
Mutation analysis
The genomic DNA was amplified for the exons of SRD5A2 gene by PCR. Using sequencing primers, the PCR products were sequenced directly with the Macrogene DNA Sequencer (Company). The variations of normal sequence obtained through applying NCBI-BLAST and Ensembl data base. The PCR products from cases and controls were subsequently sequenced again to confirm the original results.
In silico functional analysis of L73H variant
To assess the potential functional impact of the L73H (T > A substitution in codon 73), we utilized I-Mutant v.2 algorithms to perform in silico analysis. If a defined 3D (three dimensional) structure of a given protein was not available, comparative homology modeling might be the most accurate method of choice to generate the reliable tertiary protein structure using sequence information. We used the I-TASSER program [22] to generate the SRD5A2 tertiary structure and then used the PyMOL (https://www.pymol.org/) to visualize SRD5A2 products in both wild type and mutant forms. The HOPE [23] was used for more evaluation of p.L73H on the SRD5A2 product structure. The combination of the two predictive value tools, sorting intolerant from tolerant (SIFT) and polymorphism phenotyping (PolyPhen), has high accuracy on predicting pathogenicity of novel mutations [24, 25]; in this case, we used both tools.
Genotyping of V89L and A49T polymorphisms
The SRD5A2 gene was analyzed for V89L and A49T polymorphisms using restriction fragment length polymorphism (RFLP) [26]. The PCR products for the nominated polymorphisms were digested with two restriction endonucleases, RsaI and MwoI, respectively (Fig. S1). Then PCR products were electrophoresed on 14% polyacrylamide gel according to the manufacturer’s protocol.
Statistical analysis
The genotype and haplotype frequencies, also D′ value between possible pairing of V89L and A49T polymorphisms, were calculated using GENEPOP (http://genepop.curtin.edu.au/), PHASE and 2LD programs, respectively [27, 28]. The association of the hypospadias risk with V89L and A49T was verified by case–control genetic association analysis (http://www.oege.org/software/orcalc.html) and MedCalc software (http://www.medcalc.org/calc/odds_ratio.php). The most frequent homozygote genotypes in controls were used as reference values. Pearson Chi-square test was employed to calculate the deviation from Hardy–Weinberg equilibrium (HWE); p values less than 0.05 were considered in the H–W equilibrium.
Results
SRD5A2 sequencing results
We found three mutations consist of two new mutations and one previously identified mutation in cases. The clinical description of these patients is shown in Tables S1, S2. The two new mutations were located in the exon one consist of a T > A substitution in codon 73 (L73H; Fig. S2), and one nucleotide (A) that was inserted at nucleotide position 229 in codon77 [229insA] of the SRD5A2 gene (Fig. S3). In addition, we identified the previously reported substitution of the nucleotide G > A in codon 196 (G196S) in the exon 4 of SRD5A2 in one of the patients (Fig. S4).
Additionally, our sequencing results for four patients showed changes in the exon five of the SRD5A2 gene as compared with a normal sequence. Three patients had with T > A replacement in the second nucleotide of codon 256 (rs28383083; Fig. S5). Also we found three polymorphisms, rs192604242, rs72040241 and rs10529926, in one of the patients (Fig. S6).
Bioinformatics analysis
In silico analysis of the [229insA] in exon 1 showed an altered the open reading frame of the SRD5A2 gene, causing a different translation from the normal protein. In addition, the sequence translation indicated that this frame shift mutation creates an early stop codon, resulting in a truncated protein. Furthermore, we performed in silico analysis to predict functional/structural deficits conferred by the L73H mutation in SRD5A2. The 3-oxo-5-alpha-steroid 4-dehydrogenase 2 is a transmembrane protein (254 aa) that plays a central role in sexual differentiation in the androgen receptor pathway. I-Mutant V.2 showed that p.L73H slightly decreases protein stability. We used I-TASSER to perform homology modeling and obtained a tertiary structure of SRD5A2 product (Fig. S7). However, the analysis demonstrated that the mutated residue is located in a domain that is important for the main activity of the protein. Mutation of the residue might not significantly disturb this function (Table S3). Moreover, the prediction of SIFT showed that L73H has non-deleterious (neutral) function in the protein; additionally, PolyPhen shows that this is a benign substitution which does not affect the three-dimensional structures of protein (Table S3).
A49T and V89L polymorphisms
Phenotype data and frequency distribution of cases are classified as shown in Table S1. The phenotypic subgroups including glandular, midshaft and penoscrotal were observed with the most common frequencies within mild, moderate and severe phenotypes, respectively. Approximately, half of the hypospadias cases (n = 52) showed the moderate phenotype with 33% Chordee frequency (Table S1).
We found significant associations of V89L [OR 5.8; 95% CI 3.8–8.8; p 0.001 < 0.05] and A49T [OR 10.16; 95% CI 3.94–26.25; p 0.001 < 0.05] with the risk of hypospadias in our population (Table 1). The results of A49T genotype analysis revealed a high frequency of (AA) in both case and control groups, even though we found only five persons with (AT) genotype in the control group. Moreover, we did not detect the TT genotype in any control group. The less common allele (T) frequency in the control and case was (0.02) and (0.19), respectively (Table 1). SRD5A2-V89L analysis showed that the most frequent genotype between case and patient was (VL). In addition, the majority of patients had (LL) and controls had (VV) genotypes. The most frequency allele in controls and patients was V (0.63) and L (0.77), respectively (Table 1). We performed a Hardy–Weinberg equilibrium (HWE) test for both studied polymorphisms (V89L and A49T) in the SRD5A2 gene where the genotypic distributions of these polymorphisms showed a p value less than 0.05. However, the A49T polymorphism revealed a significant p value in hypospadias patients, indicating a deviation from (HWE; Table 1). Also, according to the classification of hypospadias phenotypes, the more severe clinical features, 64% of the severe group had AT genotype.
According to phenotypic severity, although the genotypic distribution varied between three mild, moderate and severe groups; the V89L and A49T polymorphisms showed the significant association with each category (p value < 0.05). Highest frequency of LL genotype of V89L was in the moderate group of cases; also AT genotype was the most frequent genotype in severe groups (Table 2).
In haplotype verification, the control group haplotypes L–T, L–A and V–A indicate informative haplotypes in the studied population. We did not detect haplotype V–T in the control group, implying a rare haplotype in the healthy ones (Table 3). Among all four possible haplotypes, the highest frequency belongs to L–A haplotype in patients (Table 3). As shown by the LD analysis in Table 3, the D′ value of pairing marker A49T-V89L was >0.3 in the hypospadias patients and controls, consistent with the χ 2 value estimated for this pairing of markers (p value < 0.05). These results support linkage disequilibrium between the two polymorphisms SRD5A2-A49T and SRD5A2-V89L in our population.
Discussion
In the present study, we investigated the association between polymorphisms in SRD5A2 gene and hypospadias disease in the Iranian population. We are the first to report mutations on the exon one of SRD5A2 gene. Our in silico analysis suggested that these mutations may change the structure and function of this gene. The newly identified L73H mutation leads to a substitution change from CTC (Leucine) to CAC (Histidine) that does not affect the enzyme function. The other new mutation [229insA] causes a truncated protein which could be deleterious, whereas the new mutations, C.229insA (G77 fs) and C.219T > A (L73H), have not been previously reported. Further research is required to determine the biological role of these mutations and the extent to which they affect enzyme activity. In addition, we identified the mutation G196S in one of our hypospadias patients which is located in the exon 4 of SRD5A2. This mutation has also been reported in previous studies [21, 29, 30].
The sequencing results suggested that the exons 1 and 4 might be hotspots for SRD5A2 mutations in Iranian hypospadias patients. We found a strong association between the A49T variant and risk of hypospadias in our population. The allele SRD5A2-A49 was the highest frequency in both patient and control groups. Previous studies have indicated that A49T mutation in SRD5A2 could be considered a risk factor for hypospadias, by reducing the level of androgens [20, 31]. Our results also showed a deviation from Hardy–Weinberg equilibrium for this polymorphism in our patients. This might be a result of TT genotype’s inconsistency with health and survival which was not even detected in previously studied groups. For instance, Pearce CL et al. could not find a TT genotype in the 1200 case and control samples [32]. Similarly, Jun Li and colleagues indicated that they observed less than 0.01% frequency of TT genotype [33].
The association between SRD5A2-V89L polymorphism and hypospadias patients has been studied in different populations [19, 21, 34]. Here, we have confirmed that the allele and genotype frequency of V89L polymorphism are different in case versus control. The SRD5A2-89L allele was more common in heterozygous and homozygous forms in the patient group. The most observed phenotype in patients, the moderate phenotype (midshaft), was associated with LL genotype of SRD5A2-V89L polymorphism.
Our results from the allele frequency estimation further suggested that the allele SRD5A2-V89 might have a protective role for hypospadias. In contrast, the allele SRD5A2-89L appears to increase the risk of hypospadias in the Iranian population. Our results therefore indicate a correlation of SRD5A2-V89L and SRD5A2-A49T with hypospadias disease in the Iranian population.
We also showed that L–A and V–A are more common haplotypes in both patient and control groups. These results may indicate that L–A haplotype confers a significant risk of hypospadias in Iranian patients. In contrast, our results indicated that V–A haplotype is associated with protection against this disease.
In conclusion, our findings suggest that two polymorphisms of SRD5A2, V89L and A49T, may harbor susceptibility to hypospadias disease. In addition to the importance of polymorphisms in this gene, SRD5A2 mutations cause in incomplete masculinization of male external genitalia and sex development; these phenotypes can range from almost normal female structures to a distinct male phenotype with ambiguous genitalia at birth. These phenotypes result from impaired conversion of testosterone to dihydrotestosterone (DHT) due to mutations in the SRD5A2 gene. Further studies in other population incorporating the DHT levels of patients and in vitro experiments (cell culture and animal studies) will provide additional insight into biological mechanisms which underlie the role of SRD5A2 and its polymorphisms in hypospadias.
References
Sagodi L, Kiss A, Kiss-Toth E, Barkai L (2014) [Prevalence and possible causes of hypospadias] A hypospadiasis gyakorisaga es lehetseges okai. Orv Hetil 155:978–985
Blaschko SD, Cunha GR, Baskin LS (2012) Molecular mechanisms of external genitalia development. Differentiation 84:261–268
Bouty A, Ayers KL, Pask A, Heloury Y, Sinclair AH (2015) The genetic and environmental factors underlying hypospadias. Sex Dev 9:239–259
Baskin LS, Ebbers MB (2006) Hypospadias: anatomy, etiology, and technique. J Pediatr Surg 41:463–472
Manson JM, Carr MC (2003) Molecular epidemiology of hypospadias: review of genetic and environmental risk factors. Birth Defects Res A Clin Mol Teratol 67:825–836
Kon M, Suzuki E, Dung VC, Hasegawa Y, Mitsui T, Muroya K, Ueoka K, Igarashi N, Nagasaki K, Oto Y et al (2015) Molecular basis of non-syndromic hypospadias: systematic mutation screening and genome-wide copy-number analysis of 62 patients. Hum Reprod 30:499–506
Di Marco C, Bulotta AL, Varetti C, Dosa L, Michelucci A, Baldinotti F, Meucci D, Castagnini C, Lo Rizzo C, Di Maggio G et al (2013) Ambiguous external genitalia due to defect of 5-α-reductase in seven Iraqi patients: prevalence of a novel mutation. Gene 526:490–493
Kim KS, Liu W, Cunha GR, Russell DW, Huang H, Shapiro E, Baskin LS (2002) Expression of the androgen receptor and 5α-reductase type 2 in the developing human fetal penis and urethra. Cell Tissue Res 307:145–153
Azzouni F, Godoy A, Li Y, Mohler J (2012) The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol 2012:530121
Bertelloni S, Baldinotti F, Russo G, Ghirri P, Dati E, Michelucci A, Moscuzza F, Meroni S, Colombo I, Sessa MR, Baroncelli GI (2016) 5α-reductase-2 deficiency: clinical findings, endocrine pitfalls, and genetic features in a large Italian cohort. Sex Dev 10:28–36
Nie M, Zhou Q, Mao J, Lu S, Wu X (2011) Five novel mutations of SRD5A2 found in eight Chinese patients with 46, XY disorders of sex development. Mol Hum Reprod 17:57–62
Shabir I, Marumudi E, Khurana ML, Khadgawat R (2012) Novel mutation of SRD5A2 gene in a patient with 5α-reductase 2 deficiency from India. BMJ Case Rep 2012:bcr2012007060
Vilchis F, Ramos L, Mendez JP, Benavides S, Canto P, Chavez B (2010) Molecular analysis of the SRD5A2 in 46, XY subjects with incomplete virilization: the P212R substitution of the steroid 5α-reductase 2 may constitute an ancestral founder mutation in Mexican patients. J Androl 31:358–364
Wang R, Dong Z, Wang W, Xiao Y, Ni J, Wang D (2013) Mutation analysis of the SRD5A2, AR and SF-1 genes in 52 Chinese boys with hypospadias. J Pediatr Endocrinol Metab 26:887–893
Zhang M, Yang J, Zhang H, Ning G, Li X, Sun S (2011) A novel SRD5A2 mutation with loss of function identified in Chinese patients with hypospadias. Horm Res Paediatr 76:44–49
Dung V, Thao B, Khanh N, Bich Ngoc C, Fukami M (2015) Phenotype and genotype of patients with disorder of sex development due to 5α-reductase deficiency. Int J Pediatr Endocrinol. doi:10.1186/1687-9856-2015-S1-P112
Skordis N, Neocleous V, Kyriakou A, Efstathiou E, Sertedaki A, Philibert P, Phylactou LA, Lumbroso S, Sultan C (2010) The IVS1-2A> G mutation in the SRD5A2 gene predominates in Cypriot patients with 5α reductase deficiency. J Endocrinol Invest 33:810–814
Giwercman YL, Abrahamsson PA, Giwercman A, Gadaleanu V, Ahlgren G (2005) The 5α-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population. Eur Urol 48:679–685
Samtani R, Bajpai M, Vashisht K, Ghosh PK, Saraswathy KN (2011) Hypospadias risk and polymorphism in SRD5A2 and CYP17 genes: case-control study among Indian children. J Urol 185:2334–2339
Silver RI, Russell DW (1999) 5alpha-reductase type 2 mutations are present in some boys with isolated hypospadias. J Urol 162:1142–1145
Thai HT, Kalbasi M, Lagerstedt K, Frisen L, Kockum I, Nordenskjold A (2005) The valine allele of the V89L polymorphism in the 5-alpha-reductase gene confers a reduced risk for hypospadias. J Clin Endocrinol Metab 90:6695–6698
Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y (2015) The I-TASSER Suite: protein structure and function prediction. Nat Methods 12:7–8
Venselaar H, Te Beek TA, Kuipers RK, Hekkelman ML, Vriend G (2010) Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces. BMC Bioinformatics 11:548
Flanagan SE, Patch AM, Ellard S (2010) Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations. Genet Test Mol Biomarkers 14:533–537
Tchernitchko D, Goossens M, Wajcman H (2004) In silico prediction of the deleterious effect of a mutation: proceed with caution in clinical genetics. Clin Chem 50:1974–1978
Cicek MS, Conti DV, Curran A, Neville PJ, Paris PL, Casey G, Witte JS (2004) Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate 59:69–76
Marchini J, Cutler D, Patterson N, Stephens M, Eskin E, Halperin E, Lin S, Qin ZS, Munro HM, Abecasis GR, Donnelly P (2006) A comparison of phasing algorithms for trios and unrelated individuals. Am J Hum Genet 78:437–450
Zhao JH (2004) 2LD, GENECOUNTING and HAP: computer programs for linkage disequilibrium analysis. Bioinformatics 20:1325–1326
Hiort O, Sinnecker GH, Willenbring H, Lehners A, Zollner A, Struve D (1996) Nonisotopic single strand conformation analysis of the 5 alpha-reductase type 2 gene for the diagnosis of 5 alpha-reductase deficiency. J Clin Endocrinol Metab 81:3415–3418
Nordenskjold A, Ivarsson SA (1998) Molecular characterization of 5α-reductase type 2 deficiency and fertility in a Swedish family. J Clin Endocrinol Metab 83:3236–3238
Baldinotti F, Majore S, Fogli A, Marrocco G, Ghirri P, Vuerich M, Tumini S, Boscherini B, Vetri M, Scommegna S et al (2008) Molecular characterization of 6 unrelated Italian patients with 5α-reductase type 2 deficiency. J Androl 29:20–28
Pearce CL, Van Den Berg DJ, Makridakis N, Reichardt JK, Ross RK, Pike MC, Kolonel LN, Henderson BE (2008) No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned. Hum Mol Genet 17:2456–2461
Li J, Coates RJ, Gwinn M, Khoury MJ (2010) Steroid 5-α-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review. Am J Epidemiol 171:1–13
Wang Y, Li Q, Xu J, Liu Q, Wang W, Lin Y, Ma F, Chen T, Li S, Shen Y (2004) Mutation analysis of five candidate genes in Chinese patients with hypospadias. Eur J Hum Genet 12:706–712
Acknowledgements
We are grateful to the medical staff of Mofid Hospital for collecting samples. This study was supported by a grant from the Research Dean of Shahid Beheshti University of Medical Sciences.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
This informed consent form collected from parents of children between 1 and 4 years of age who attended to Mofid Children’s Hospital, and who were asking to participate in the study.
Additional information
R. Mirfakhraie, M. D. Omrani have contributed equally to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Rahimi, M., Ghanbari, M., Fazeli, Z. et al. Association of SRD5A2 gene mutations with risk of hypospadias in the Iranian population. J Endocrinol Invest 40, 391–396 (2017). https://doi.org/10.1007/s40618-016-0573-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-016-0573-y